skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

74 Total results for product and free and sample content found

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Survival Data Boost Lilly & Novartis's CDK4/6 Assault On Pfizer's Ibrance In Metastatic Breast Cancer

By Alex Shimmings 18 Oct 2019

Pfizer’s dominance of the CDK4/6 inhibitor market will come under renewed pressure as the MONALEESA-3 and MONARCH-2 studies for Novartis’s Kisqali and Lilly’s Verzenio presented at ESMO confirmed their survival benefits in advanced hormone-receptor-positive, HER2-negative breast cancer. The data firmly push the drug class into front-line advanced setting in these patients.

Topic cancer drug-development-landscape research

Medtech Insight: 世界の医療機器・医療技術の最新情報

Exact Sciences Buys Genomic Health In $2.8Bn Expansion Deal

06 Aug 2019

Exact Sciences Buys Genomic Health In $2.8Bn Expansion Deal

Cancer diagnostics company Exact Sciences is combining with Genomic Health in a major merger valued at $2.8bn. The combined company will offer two of the fastest growing brands in cancer diagnostics, Cologuard and Oncotype DX.

Topic cancer business-strategies

Medtech Insight: 世界の医療機器・医療技術の最新情報

UK Plan To Speed Access To ‘Cutting-Edge’ Products

By Ian Schofield 03 Jul 2019

UK Plan To Speed Access To ‘Cutting-Edge’ Products

Changes are being made to the UK’s Accelerated Access Collaborative to help streamline access to ground-breaking medicines and diagnostic tools in areas like dementia, diabetes and cancer.

Topic business-strategies cancer diabetes

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Pfizer's Three-Pronged Oncology Strategy Includes Expanding Ibrance, Xtandi, Developing Blockbuster Combos

02 Jul 2019

Pfizer's Three-Pronged Oncology Strategy Includes Expanding Ibrance, Xtandi, Developing Blockbuster Combos

Xtandi use in early prostate cancer, lorlatinib as second-line treatment for non-small cell lung cancer and dacomitinib for first-line NSCLC have upcoming user fee dates.

Topic cancer

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Imbruvica Replaces Chemo, Darzalex Boosts Standard Of Care In Front-Line CLL, Myeloma

02 Jul 2019

Imbruvica Replaces Chemo, Darzalex Boosts Standard Of Care In Front-Line CLL, Myeloma

Late-breaker presentations at ASH showed that replacing chemotherapy agents with Imbruvica in CLL, and adding Darzalex to Revlimid and dexamethasone in multiple myeloma, is more effective than current standards of care in certain front-line settings.

Topic Cancer Drug approval

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Downward, Eastward or Inward? Blockbuster Film Puts Cancer Drug Prices In China Spotlight

02 Jul 2019

Downward, Eastward or Inward? Blockbuster Film Puts Cancer Drug Prices In China Spotlight

Bagging a $200m box office in its opening week in China, "Dying to Survive" is a sentimental movie about a Chinese businessman selling cancer drugs smuggled from India but unapproved in China that sees his life taking a drastic turn, from convicted felon to a Robin Hood-like hero as he helps those in need. The Chinese film authority’s clearance for the screening of the movie and the smash success signal three key messages about the future potential direction of oncology drugs in the country.

Topic cancer

Trialtrove: 医療用医薬品の臨床試験情報データベース

がん臨床試験に対する投資額の効果を探る

25 Jun 2019

がん臨床試験に対する投資額の効果を探る無料ホワイトペーパー「A Decade in Review: Oncology Trial Benchmarks and Sponsor Analysis」が発行されました。競争が激しくなる中、医薬品業界全体で様々なレベルの投資が行われており、新薬を市場に投入するための平均コストは上昇し続けています。このような投資額の増加は臨床試験の実施状況にどのような影響を与えているのでしょうか。

Topic clinical-trials cancer

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Multiple Myeloma Pricing, Reimbursement, and Access

13 Jun 2019

Disease management and treatment programmes change, as research evolves and new discoveries are made. Your market access strategies must evolve too.

Topic cancer drug-development-landscape reimbursement

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。